论文部分内容阅读
目的建立裸鼠非小细胞肺癌(NSCLC)H460细胞动物模型,观察环氧化酶2(COX-2)选择性抑制剂塞来昔布(Celecoxib)对H460放疗的增敏作用,并对其作用机理进行初步探讨。方法建立Balb/c裸鼠肿瘤模型。动物随机分成3组:对照组、放疗组、塞来昔布+放疗组。灌肠法给予塞来昔布16mg/kg/d,4周时对比两组肿瘤瘤重;免疫组化方法分析共济失调-毛细血管扩张症突变蛋白(ATM)和表皮生长因子受体(EGFR)表达变化。结果 4周时塞来布昔+放疗组与放疗组的抑瘤效果比较有显著差异(P<0.05)。结论塞来昔布可能通过提高ATM和EGFR的表达,增强H460细胞的放疗敏感性,将来可能具有较好的临床应用价值。
Objective To establish an animal model of H460 cell line in nude mice with non-small cell lung cancer (NSCLC) and observe the sensitizing effect of Celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, on H460 radiotherapy. Mechanism to conduct a preliminary discussion. Methods Balb / c tumor model was established in nude mice. The animals were randomly divided into 3 groups: control group, radiotherapy group, celecoxib + radiotherapy group. Celecoxib 16 mg / kg / d was administrated by enema and the tumor weight was compared at 4 weeks. Immunohistochemistry was used to analyze ataxia-telangiectasia mutant protein (ATM) and epidermal growth factor receptor (EGFR) Change of expression Results At 4 weeks, the antitumor effects of celecubox + radiotherapy group and radiotherapy group were significantly different (P <0.05). Conclusion Celecoxib may enhance the radiosensitivity of H460 cells by increasing the expression of ATM and EGFR and may have a better clinical value in the future.